TECHNICAL ADVANCE

- LAA Occluder View for post-implantation Evaluation (LOVE) - standardized imaging proposal evaluating implanted left atrial appendage occlusion devices by cardiac computed tomography

Michael Behnes1†, Ibrahim Akin1†, Benjamin Sartorius1, Christian Fastner1, Ibrahim El-Battrawy1, Martin Borggrefe1, Holger Haubenreisser2, Mathias Meyer2, Stefan O. Schoenberg2 and Thomas Henzler2

Abstract

Background: A standardized imaging proposal evaluating implanted left atrial appendage (LAA) occlusion devices by cardiac computed tomography angiography (cCTA) has never been investigated.

Methods: cCTA datasets were acquired on a 3rd generation dual-source CT system and reconstructed with a slice thickness of 0.5 mm. An interdisciplinary evaluation was performed by two interventional cardiologists and one radiologist on a 3D multi-planar workstation. A standardized multi-planar reconstruction algorithm was developed in order to assess relevant clinical aspects of implanted LAA occlusion devices being outlined within a pictorial essay.

Results: The following clinical aspects of implanted LAA occlusion devices were evaluated within the most appropriate cCTA multi-planar reconstruction: (1) topography to neighboring structures, (2) peri-device leaks, (3) coverage of LAA lobes, (4) indirect signs of neo-endothelialization. These are illustrated within concise CT imaging examples emphasizing the potential value of the proposed cCTA imaging algorithm: Starting from anatomical cCTA planes and stepwise angulation planes perpendicular to the base of the LAA devices generates an optimal LAA Occluder View for post-implantation Evaluation (LOVE). Aligned true axial, sagittal and coronal LOVE planes offer a standardized and detailed evaluation of LAA occlusion devices after percutaneous implantation.

Conclusions: This pictorial essay presents a standardized imaging proposal by cCTA using multi-planar reconstructions that enables systematical follow-up and comparison of patients after LAA occlusion device implantation.

Keywords: LAA occlusion device, LAA occluder, Cardiac CTA, Peri-device leak, Lobe coverage, Neo-endothelialization, Thrombus
Background
The left atrial appendage (LAA) represents the main origin of thrombus formation in atrial fibrillation, where the principles of Virchow’s triad, such as dysfunction and structural changes of the endothelium as well as abnormal blood stasis and homoeostasis are present [1–3]. The implantation of LAA occlusion devices in patients with atrial fibrillation was shown to prevent cardio-embolic stroke as safe and effective as the treatment with the oral anticoagulant warfarin in patients eligible for oral anticoagulation [2–10]. However, the anatomic morphology of the LAA is highly variable and influences independently the incidence of cardio-embolic stroke [11, 12]. The common classification distinguishes four different LAA morphologies, which can be evaluated at best by computed tomography imaging [12–14]: 1. chicken wing, 2. cactus, 3. windsock, 4. cauliflower. All these morphologies differ extremely by the number of different LAA lobes, folds, tortuositides, diameters and global sizes and complicate individually the percutaneous implantation of LAA occlusion devices. Interestingly, the chicken wing was shown to be associated with lowest rates of cardio-embolic stroke compared to all other LAA morphologies [12].

The WATCHMAN (WM) (Boston Scientific, Natick, MA, USA) and Amplatzer Cardiac Plug (ACP) (St. Jude Medical, St Paul, MN, USA) represent the most commonly implanted LAA occlusion devices with valuable scientific evidence being available at present [2, 7, 15, 16]. Until now, trans-esophageal echocardiography (TEE) is most often applied to guide LAA occlusion device implantation, positioning and sealing both during percutaneous intervention and follow-up after device implantation [17–19]. It was shown that healing response after implantation of these devices differs and might result in harmful impact on neighboring structures [20]. However, a standardized imaging proposal for post-implantation evaluation of LAA occlusion devices by cardiac computed tomography (cCTA) has never been developed.

Therefore, this pictorial essay aims to develop this standardized imaging proposal by cCTA in order to analyze relevant clinical aspects of LAA occlusion devices after percutaneous implantation. This cCTA imaging proposal outlines relevant clinical aspects such as device positioning in relation to the varying morphology and topography of the LAA as well as functional device aspects such as peri-device leaks, lobe coverage and neo-endothelialization of the device and demonstrates illustrations of these conditions.

Methods
Ethics, consent and permissions
All participants of the presented patient-related data within this pictorial assays gave written consent to this analysis. The analyses were carried out according to the principles of the declaration of Helsinki and was approved by the medical ethics commission II of the Faculty of Medicine Mannheim, University of Heidelberg, Germany.

Cardiac CTA (cCTA) protocol and image reconstruction advice for post-implantation evaluation of LAA occlusion devices
Based on our experience, cCTA protocols for the evaluation of LAA occlusion devices do not require significant protocol adjustments, when compared to standard cCTA protocols being performed for the evaluation of coronary artery stenosis [21–24]. Optimal hydration of the patient is recommended in order to achieve best measurements. Similar to a standard cCTA acquisition contrast injection should be performed with a flow rate of at least 5 cc/s followed by a saline chaser in order to have a compact contrast bolus that is washed out mainly in the right atrium and right ventricle during the image acquisition. Depending on the patients’ heart rate all available cCTA acquisition protocols in principle qualify for the evaluation of LAA occlusion devices including traditional retrospective ECG gating, prospective ECG triggering as well as high pitch or single heart beat acquisitions [25]. However, since there is no dedicated recommendation and clinical requirement for post-implantation evaluation of LAA occlusion devices in all patients, the acquisition technique that provides the lowest radiation dose depending on the available CT system should be applied. Hereby, a slightly lower image quality of the coronary arteries can be accepted since the LAA is not prone particularly to motion artifacts such as for instance the right coronary artery. Prospective ECG triggered cCTA acquisitions or single heart beat acquisitions can be used in patients with high heart rates or arrhythmias. However, different to a standard cCTA in patients with a low and regular heart rate an end-systolic image acquisition was applied for the evaluation of LAA occlusion devices in all patients independently from the heart rate in order to acquire the image data during the maximum distension of the left atrium and LAA.

Reconstruction of cCTA raw data was performed with a slice thickness between 0.5 and 0.6 mm using a sharp convolution kernel that is also used for the reconstruction of cCTA images in patients with coronary artery stent grafts or heavily calcified plaques. If available iterative reconstruction techniques should be used to lower image noise and blooming artifacts originating from metal components of the devices [26–28]. Table 1 summarizes the proposed cCTA protocol of patients after LAA occlusion device implantation.
### Table 1 Protocol example for imaging of LAA occlusion devices using a 3rd generation dual source CT system

| cCTA technique | Tube voltage | Tube current-time product | Slice thickness | Reconstruction increment | Reconstruction kernel | Reconstruction phase | Contrast medium |
|----------------|--------------|---------------------------|----------------|--------------------------|----------------------|---------------------|-----------------|
| High pitch single heart beat acquisition | BMI <28: 70 kVp | Automated tube current modulation (Care Dose 4D, Siemens) | 0.6 mm | 0.4 | Bv40 (vascular kernel) | 70 % RR | 80 cc iomeprol 400 (Bracco) |
| Prospective ECG gating (step-and-shot) | BMI <28: 70 kVp | Automated tube current modulation (Care Dose 4D, Siemens) | 0.6 mm | 0.4 | Bv40 (vascular kernel) | 40–70 % RR | 80 cc iomeprol 400 (Bracco) |
| Retrospective ECG gating | BMI <28: 70 kVp | Automated tube current modulation (Care Dose 4D, Siemens) | 0.6 mm | 0.4 | Bv40 (vascular kernel) | 20–70 % RR | 80 cc iomeprol 400 (Bracco) |
| Retrospective ECG gating | BMI <28: 70 kVp | Automated tube current modulation (Care Dose 4D, Siemens) | 0.6 mm | 0.4 | Bv40 (vascular kernel) | 10–90 % RR | 80 cc iomeprol 400 (Bracco) |

Note: bpm: beats per minute; kVp: kilovoltage peak; ECG: electrocardiogram; contrast material is not reduced as it is possible for a standard coronary CT angiography in order to reduce blood stasis artifacts within the left atrial appendage; the scan start is determined using bolus tracking within the descending aorta using a threshold of 120 HU and an additional delay of 7 s in order to have a slightly delayed scan start when compared to standard acquisition.

### Generating a standardized proposal by multi-planar imaging

0.6 mm thick images reconstructed with a medium convolution kernel are uploaded on a simple 3D multi-planar rendering workstation with the 3 planes locked at a 90° angle (Figs. 1 and 2, panels I) (Additional files 1 and 2). The axial slices should be moved to the level of the left atrium, in which the LAA occlusion device is visible (Figs. 1 and 2, panels II). These initial steps are independent of different type of implanted LAA occlusion devices (either WM or ACP).

### Amplatzer cardiac plug (ACP) device

Specifically for the ACP device, move the coronal axis within the transverse window perpendicular to the disc of the ACP device (Fig. 1, panel III). Afterwards, align the axes on the two other viewers also perpendicular to the disc of the ACP device (Fig. 1, panels IV and V). Lastly, the center of the axes should be placed to the center of the screw-hub.

### WATCHMAN (WM) device

Since the WM device is not equipped with a disc, the alignment might become more challenging. Here, using maximum intensity projection (MIP) images with a slab thickness of approximately 10 mm allows visualization of the whole nitinol frame of the WM device. Afterwards, move the coronal axis within the transverse window perpendicular to the coves of the parachute of the WM device (Fig. 1, panel III). Afterwards, align the axes on the two other viewers also perpendicular to the coves of the parachute of the ACP device (Fig. 1, panels IV and V). Lastly, the center of the axes should be placed to the center of the screw-hub.

### Results

#### Clinical scenarios reflecting relevant clinical aspects after implantation of LAA occlusion devices

Imaging reports about percutaneously implanted LAA occlusion devices should focus on the following important clinical aspects:

- Global positioning of the device including rotation around the entry axis to the LAA. This can be best measured on LOVE axial and LOVE sagittal views.
LOVE axial views allow optimal evaluation of global compression of both devices:
- WM device: compression of 10–20% referred to the original device size is recommended.
- ACP device: concave disc; device lobe positioned 2/3 distal to the LCX inside and engaged within the LAA; ACP device axis in line with the LAA neck axis.

LOVE axial views allow optimal evaluation of impairment to neighboring structures by the LAA occlusion device: including positioning in relation to the mitral valve annulus, pulmonary artery, left pulmonary veins as well as LCX that is best visible in LOVE axial views (Fig. 3).

**Functional aspects of LAA occlusion devices**

- Peri-device leaks:
  These can be seen best on LOVE sagittal views. The presence of a peri-device leak should be measured in all reports (Figs. 4, 5 and 6). Higher resolution measurements of peri-device leak diameters can be performed by cCTA compared to TEE. Accordingly, further studies are needed to evaluate the additional value of cCTA measurements in this context and whether definitions of the PROTECT AF study can accordingly be transferred (i.e. minor (<1 mm width), moderate (1 to 3 mm width) or major.
A sole peri-device leak should be reported in case the sealing part of the device (either proximal disk or cap) is parallel to the plane of the LAA ostium. Remaining contrast filling will then be visible around the device on the LOVE views (Fig. 6).

- Coverage of all lobes:
The LAA often consists of different lobes not corresponding necessarily to the fixed shape of the LAA occlusion device. Therefore, complete coverage of all LAA lobes is not always achievable.

Assessment of lobe coverage should consider the angle between the sealing part of the device (either proximal disk or cap) and the plane of the LAA ostium. This angle corresponds to the incompletely covered LAA lobe. Accordingly, Fig. 7 illustrates a small residual LAA lobe due to over-angulation of the device. Rotation around the entry axis to the LAA should be measured on LOVE axial and LOVE sagittal views. Lobe coverage should be assessed on all LOVE reformations (Figs. 4, 5, 7 and 8).
Complete neo-endothelialization:
Absence of contrast enhancement within the LAA without any peri-device leak suggests complete neo-endothelialization. Accordingly, contrast enhancement in the LAA of less than 50 Hounsfield units compared to the left atrium suggests incomplete neo-endothelialization. Equal contrast enhancement in both LAA and left atrium suggests no or very early stages of neo-endothelialization (Figs. 4, 5, 7 and 8).

Discussion
This pictorial essay presents a standardized imaging proposal by cCTA using multi-planar reconstructions that enables systematical follow-up and comparison of patients after LAA occlusion device implantation. As described above and being accompanied by a case series of striking illustrations this imaging proposal intends to cover the most relevant clinical challenges of implanted LAA occlusion devices including morphologic, topographic as well as functional device-related aspects. The presented imaging proposal generates novel hypotheses, which have to be proven by ongoing prospective, randomized imaging studies.

Based on the so far available literature on safety and patient outcome, it is likely that the number of patients undergoing percutaneous LAA occlusion device implantation will raise significantly within the near future similar to the growing number of patients undergoing transcatheter aortic valve replacement (TAVR). However, in order to identify patients with poor outcome and/or post-procedural complications, such as a residual LAA larger than a specific device size that still leads to thrombus formation, accurate, reproducible and reader-independent imaging is crucial. This is of particular importance in order to generate more evidence about optimal placement of LAA occlusion devices.

For instance, the presence of relevant peri-device leaks or incomplete coverage of residual LAA lobes might be
Fig. 5 LOVE - axial (panel a), sagittal (panel b), coronal (panel c), and 3D (panel d) reformations of a 72-year-old male patient who underwent cardiac CTA 9 months after implantation of a ACP® LAA occlusion device. Panels a, b, and c show optimal positioning of the device with no peri-device leak, complete lobe coverage as well as complete neo-endothelialization of the device suggested by the absence of contrast enhancement < 50 Hounsfield units in the LAA (* in B and C). Volume rendered reconstructions.

Fig. 6 LOVE - axial (panel a), sagittal (panel b), and coronal (panel c) reformations of a 80-year-old male patient who underwent cardiac CTA 8 months after implantation of a WATCHMAN® LAA occlusion device. Panels a and c show a small peri-device leak < 3 mm at the cranial LAA entry causing complete contrast filling of the LAA (white arrow). Panel b demonstrates the correct positioning of the device with complete lobe coverage, as indicated by the correctly positioned sealing part (proximal cap of the WM device) parallel to the plane of the LAA ostium (red line). Due to the presence of the peri-device leak the assessment of endothelialization is not feasible with cardiac CTA.
associated with individually impaired neurologic outcome of the patients. These mal-appositions of LAA occlusion devices have been attributed to clinical overt neurologic disability and silent cerebral ischemia being caused by cerebral micro-embolism and visualized by cerebral magnetic resonance imaging (cMRI) [17]. Importantly, cCTA might also allow the evaluation of complete neo-endothelialization of the LAA occlusion device. From the treating physician’s perspective complete neo-endothelialization without any peri-device leak might facilitate future clinical decision-making to stop concomitant anticoagulation or dual antiplatelet therapy (DAPT).

Little is known regarding incidences of device related complications after successful percutaneous implantation of LAA occlusion devices, such as device compression, peri-device leaks, lobe coverage and progress of neo-endothelialization related to study-specific anti-thrombotic treatments. The latter were evaluated for DAPT (i.e. aspirin and clopidogrel) lasting 6 months, as within the present study, or for warfarin for 45 days, followed by clopidogrel for 4.5 months and lifelong aspirin [2, 7, 10, 16]. There is a lack of data comparing the quality of TEE versus CT follow-up imaging after device implantation and the optimal time period still needs to be investigated. Device compression and shape in relation to surrounding vessels is of importance for optimal device and hemodynamic stability over time in order to prevent relevant dislodgment or obstruction of neighboring structures as being recommended by the manufacturer [29]. It was shown recently, that compression and shape of LAA occlusion devices are changing temporarily within three months after implantation, however its clinical relevance besides complete LAA closure is still under debate [30, 31].

Furthermore, accurate differentiation between thrombus formation and blood stasis within the LAA is challenging using standard cCTA. An additional delayed cCTA approximately 70 s after the start of the contrast injection is recommended [32]. Imaging the patients in prone position is another theoretical approach in order to minimize the effects of blood stasis in the LAA. However, data is lacking about the usefulness of performing cCTA in a prone position. Dual energy cCTA using calculated iodine maps has been proposed in order to differentiate accurately blood stasis from thrombus formation within the LAA of patients with cardio-embolic stroke [33].

As outlined, post procedural image analysis with cCTA might bear the potential of a standardized imaging using defined multi-planar reformations that best display the complex 3-dimensional shape of the LAA and the device. In our opinion, cCTA has the main advantage that the images can be very standardized analyzed and reconstructed.
and make quantitative measurements reliable. This is of particular importance to generate more evidence on relevant clinical questions: (1) What size of a residual LAA is acceptable with different devices? (2) What size of peri-device leaks still leads to a complete occlusion over time? However, the advantages of cCTA for post-implantation LAA occlusion device evaluation have to outweigh the patients’ individual risk being associated with an additional radiation dose and additional administration of iodinated material.

Potential value and limitations of cardiac CTA in the context of LAA occlusion devices
Cardiac CTA allows the comprehensive non-invasive visualization of the whole heart including coronary arteries as well as all important neighboring structures of the LAA and thus accurate evaluation of post-implantation evaluation of LAA occlusion devices by the described LOVE view. The main arguments for the use of cCTA in this context, besides its non-invasiveness, are firstly, the whole volume coverage with a high spatial resolution and secondly, the high reproducibility of the technique that allows to angulate the isotropic dataset retrospectively after the procedure in all desired projections. Thereby generating an investigator’s independency, cCTA becomes particularly attractive for clinical studies that require a high standardization of follow-up examinations. Thirdly, image artifacts do not hamper cCTA image quality because all available LAA occlusion devices do not lead to metal artifacts such as other metal implants. Based on our experience, cCTA allows assessing all relevant clinical questions including indirect visualization of LAA occlusion device neo-endothelialization if no peri-device leak is present. For instance, no contrast enhancement within the LAA suggests complete neo-endothelialization, whereas contrast enhancement in the LAA of less than 50 Hounsfield units compared to the enhancement within the left atrium suggests incomplete neo-endothelialization. Contrast enhancement within the LAA that is equal to the left atrium suggests no or very early stages of neo-endothelialization.

The main concerns with cCTA in the context of LAA occlusion device evaluation are the additional radiation dose that is given to the patient. However, with low radiation dose techniques of state-of-the-art CT systems the radiation dose has been reduced significantly over the past 5 years [25]. Thus, the risk of ionizing radiation in this mainly elderly population should be weighted clinically against potential overseen significant clinical findings potentially being detected by cCTA (such as thrombus formation or indirect signs of incomplete neo-endothelialization), whereas their clinical impact still needs to be proven within prospective clinical studies.

The second relevant concern of cCTA is the need for iodinated contrast material, which is crucial in patients with impairment of renal function. Although the amount of contrast material for the evaluation of LAA occlusion devices can be reduced to a minimum of 30–40 cc of contrast in patients with elevated serum creatinine levels, the indication should be checked strictly in patients with serum creatinine levels above 1.5 mg/dL. Additionally, cCTA is more expensive and not as widely available compared to echocardiography.

Conclusions
This pictorial essay describes a standardized imaging proposal including examples of (ab)normal findings after percutaneous implantation of LAA occlusion devices. Whether the proposed cCTA imaging instructions might facilitate future clinical follow-up, cost effectiveness and therapeutic decisions needs to be evaluated further in larger, prospective and randomized imaging studies evaluating this specific subset of cardiac patients.

Additional files

Additional file 1: Movie demonstrating the generation of the LAA Occluder View for post-implantation Evaluation (LOVE) for the Amplatzer cardiac plug (ACP) device by cardiac CTA. (MP4 7602 kb)

Additional file 2: Movie demonstrating the generation of the LAA Occluder View for post-implantation Evaluation (LOVE) for the WATCHMAN (WM) device by cardiac CTA. (MP4 8524 kb)

Additional file 3: Movie revealing the potential diagnostic insights of cardiac CTA imaging for an implanted ACP device by optimal alignment of LOVE planes. (MP4 4653 kb)

Additional file 4: 3D animation illustrating optimal implantation of an ACP device within the LAA after optimal alignment of LOVE planes by cardiac CTA. (MP4 3466 kb)

Abbreviations
ACP: amplatz cardiac plug; BMBF: German Ministry of Education and Research; cCTA: cardiac computed tomography; cMRT: cerebral magnetic resonance imaging; CT: computed tomography; DAPT: dual antiplatelet therapy; DZHK: Deutsches Zentrum für Herz-KreislauForschung - German Centre for Cardiovascular Research; LAA: left atrial appendage; LOVE: LAA occluder view for post-implantation evaluation; MIP: maximum intensity projection; TEE: tranesophageal echocardiography; WM: Watchman.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
MBo conceived the study, participated in its design and coordination, performed imaging analysis, participated in data analysis and interpretation and drafted the manuscript. IA conceived the study, participated in its design and coordination, performed imaging analysis, participated in data analysis and interpretation and drafted the manuscript. BS participated in the study design and coordination, data acquisition and analysis, and helped to draft the manuscript. IE-B participated in the study design and coordination, data acquisition and analysis, and helped to draft the manuscript. MB participated in the study design and coordination, data acquisition and analysis, and helped to draft the manuscript. MM participated...
References

1. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation. Virchow's triad revisited. Lancet. 2009;373(9658):155–66.
2. Bergmann MW, Landmesser U. Left atrial appendage closure for stroke prevention in non-valvular atrial fibrillation: rationale, devices in clinical development and insights into implantation techniques. EuroIntervention. 2014;10(4):407–504.
3. Camm AJ et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47.
4. Alli O et al. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvar atrial fibrillation. J Am Coll Cardiol. 2013;61(17):1790–8.
5. Bayard YL et al. PLATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulable eligible atrial fibrillation patients: results from the European PLATO study. EuroIntervention. 2010;6(2):220–6.
6. Nietlispach F et al. Amplatz left atrial appendage occlusion: single center 10-year experience. Catheter Cardiovasc Interv. 2013;82(2):283–9.
7. Reddy VY et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study. J Am Coll Cardiol. 2013;61(20):2551–6.
8. Urena M et al. Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvar atrial fibrillation and contraindications to anticoagulation therapy. J Am Coll Cardiol. 2013;62(2):96–102.
9. Wiebe J, et al. Safety of percutaneous left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation and contraindications to anticoagulation therapy. Catheter Cardiovasc Interv. 2014;83(5):796–802.
10. Holmes Jr DR et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1–12.
11. Anselmino M et al. Left atrial appendage morphology and silent cerebral ischemia in patients with atrial fibrillation. Heart Rhythm. 2014;11(1):2–7.
12. Di Biase L et al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol. 2012;60(9):531–8.
13. Laura DM et al. The role of multimodality imaging in percutaneous left atrial appendage suture ligation with the LARIAT device. J Am Soc Echocardiogr. 2014;27(7):699–708.
14. Lopez-Minguez JR, et al. Anatomical Classification of Left Atrial Appendages in Specimens Applicable to CT Imaging Techniques for Implantation of Amplatzer Cardiac Plug. J Cardiovasc Electrophysiol. 2014;25(9):976–84.
15. Holmes DR et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534–42.
16. Reddy VY et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial. Circulation. 2013;127(6):720–9.
17. Viles-Gonzalez JF et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. J Am Coll Cardiol. 2012;59(10):923–9.
18. Viles-Gonzalez JF et al. Incomplete occlusion of the left atrial appendage with the percutaneous left atrial appendage transcatheter occlusion device is not associated with increased risk of stroke. J Intracard Electrophysiol. 2012;33(1):69–75.
19. Anter E, et al. Comparison of intracardiac echocardiography and transesophageal echocardiography for imaging of the right and left atrial appendages. Heart Rhythm. 2014.
20. Kar S et al. Impact of Watchman and Amplatzer Devices on Left Atrial Appendage Adjacent Structures and Healing Response in a Canine Model. JACC Cardiovasc Interv. 2014;7(7):801–9.
21. Mahesh M, Cody DD. Physics of cardiac imaging with multiple-row detector CT. Radiographics. 2007;27(5):1495–509.
22. Schoepf UJ et al. CT coronary angiography: indications, image acquisition, and interpretation. Radiolologia. 2008;50(2):113–30.
23. Weininger M et al. Cardiothoracic CT angiography: current contrast medium delivery strategies. AJR Am J Roentgenol. 2011;196(3);W260–72.
24. Xu L, Zhang Z. Coronary CT angiography with low radiation dose. Int J Cardiovasc Imaging. 2010;26 Suppl 1:17–25.
25. Hender T et al. Practical strategies for low radiation dose cardiac computed tomography. J Thorac Imaging. 2010;25(3):213–20.
26. Ebersberger U et al. CT evaluation of coronary artery stents with iterative image reconstruction: improvements in image quality and potential for radiation dose reduction. Eur Radiol. 2013;23(1):125–32.
27. Moscarello A et al. Coronary CT angiography: image quality, diagnostic accuracy, and potential for radiation dose reduction using a novel iterative image reconstruction technique-comparison with traditional filtered back projection. Eur Radiol. 2011;21(10):2130–8.
28. Renker M et al. Evaluation of heavily calcified vessels with coronary CT angiography: comparison of iterative and filtered back projection image reconstruction. Radiology. 2011;260(2):390–9.
29. Corporation, B.S. WATCHMAN™ 12 F Left Atrial Appendage Closure Device with Delivery System. 2014; Instruction for Use. Available from: http://www.bostonscientific.com/watchman-de/assets/pdf/WATCHMAN_DU_90893601-01A.pdf.
30. Neuzner J et al. Left atrial appendage closure with the Amplatzer Cardiac Plug: Rationale for a higher degree of device oversizing at implantation. J Cardiol. 2015;22(2):201–5.
31. Sepahpour A et al. Death from pulmonary artery erosion complicating implantation of percutaneous left atrial appendage occlusion device. Heart Rhythm. 2013;10(12):1810–1.
32. Romero J et al. Detection of left atrial appendage thrombus by cardiac computed tomography in patients with atrial fibrillation: a meta-analysis. Circ Cardiovasc Imaging. 2013;6(2):185–94.
33. Hur J et al. Cardioembolic stroke: dual-energy cardiac CT for differentiation of left atrial appendage thrombus and circulatory stasis. Radiology. 2012;263(3):688–95.